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Abstract
BACKGROUND: Lymphoblastic lymphoma (LL) comprises approximately 20% of childhood non-Hodgkin lymphoma (NHL); 
however, few studies had investigated the role of 18F-FDG-PET/CT in pediatric LL patients. We aim in this study to assess the 
role of 18F-FDG-PET/CT in the initial staging of newly diagnosed pediatric patients with LL as well as in the assessment of re-
sponse after induction chemotherapy.
PATIENTS AND METHODS: A prospective study enrolled biopsy proven newly diagnosed pediatric LL patients presenting 
in the Children Cancer Hospital Egypt (CCHE) during the period from October 2014 to October 2016. 18F-FDG-PET/CT was 
done initially before therapy and after induction chemotherapy in all patients. The patients were followed until the end of April 
2018 (mean 23.5 months). 
RESULTS: All lymphoma involvement lesions (n = 43) were FDG avid and the intensity of nodal FDG uptake was variable. 
Two patients (11%) had bone marrow (BM) involvement by < 25% blast cells with corresponding positive BM focal uptake in 
18F-FDG-PET/CT (SUVmax = 4 and 4.5). Evaluation post induction phase; CT detected 8 residual lesions in 8 patients (44.4%), 
while 18F-FDG-PET/CT detected only 3 Deauville-positive residual lesions in 3 patients (16.6%). No intensification of therapy was 
done in all post-induction positive patients. Repeated 18F-FDG-PET/CT at week 18 for post-induction patients revealed cleared 
all Deauville-positive residual lesions. On the other hand, repeated CT at week 18 detected regression but still residual in 4/8 
(50%) post-induction CT lesions with clearance of the rest (50%).
CONCLUSION: In initial staging, 18F-FDG-PET/CT is a useful tool for disease extent evaluation of pediatric LL. Moreover, it 
could provide a diagnostic hint for BM involvement. 18F-FDG-PET/CT done after induction therapy has a good negative predic-
tive value with higher specificity than CT alone, but is not an indication for treatment intensification due to false positive results. 
However, larger sample size is required for better conclusion. 
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Background
Lymphoblastic lymphoma (LL) comprises approximately 
20% of childhood non-Hodgkin lymphoma (NHL) [1]. Precursor 
T-lymphoblastic (T-LL) subtype constitutes 75% of LL cases, with 
the remainder being precursor B-cell LL (B-LL) [2].
Clinical presentation of LL varies according to immune-phe-
notype. T-cell lymphoblastic lymphomas most commonly involve 
the supra-diaphragmatic lymph nodes, especially the anterior 
mediastinum [3]. On the other hand, B-LL are usually localized in 
peripheral lymph nodes and extra-nodal sites such as soft tissues, 
skin and bone [4]. 
18F-FDG-positron emission tomography/computed tomography 
(18F-FDG-PET/CT) is emerging as a potential non-invasive diagnos-
tic modality for initial staging as well as assessment of response 
to therapy and follow-up in pediatric oncology [5]. However, few 
studies had investigated its role in LL separately, especially in 
children [6]. 
The aim of this study was to explore the potential role of 
18F-FDG-PET/CT in the initial staging of newly diagnosed pediatric 
patients with lymphoblastic lymphoma (LL) as well as in the as-
sessment of response to therapy after induction chemotherapy.




This prospect ive study included 18 pediatr ic pa-
tients (14 males and 4 females; median age, 13 years) who were 
diagnosed and treated for histopathologically confirmed LL at the 
CCHE during the period from October 2014 to October 2016 and 
followed until April 2018.  
All Patients were treated according to St. Jude Children 
Research Hospital ALL Total Therapy XV protocol, standard risk 
arm [7]. Staging was done following Murphy’s classification [8]
highlighting natural history, management, and end results, em-
phasizing dissimilarities from lymphomas occurring in adult years. 
Childhood will arbitrarily be defined as the period from infancy to 
adulthood, encompassing adolescence, rougly up until the fifteenth 
to eighteenth years of life. The lymphomas typical of childhood 
naturally do not vanish at an arbitrary upper threshold in maturity 
but rather decline in frequency. A separate emphasis on childhood 
NHL is warranted for numerous reasons, not the least being that 
a better insight into ontogeny may be gained. Children experience 
a different spectrum of malignant disease than adults do, the 
common sites of origin typically being embryonal tissues of the 
hematopoietic system, central and sympathetic nervous system 
(including the eye and the adrenal. 
As part of the baseline staging work-up, all patients underwent 
whole-body 18F-FDG-PET/CT scanning; contrast-enhanced CT of 
the chest, abdomen, and pelvis; and bone marrow aspiration (BMA) 
and biopsy (BMB), cerebrospinal fluid examination (CSF) and se-
rum lactate dehydrogenase (LDH) level measurement. Evaluation 
post-induction therapy was done by 18F-FDG-PET/CT, (+/- BMA 
and BMB which were repeated for initially positive patients only). 
18F-FDG-PET/CT was also repeated at week 18 maintenance for 
positive post-induction patients. 
Evaluation of treatment response post induction was done 
according to CT and BMB, 18F-FDG-PET/CT according to the 
International Pediatric NHL Response Criteria (IRC) [9].
18F-FDG-PET/CT procedure
Whole body 18F-FDG-PET/CT studies were conducted ac-
cording to the European Association of Nuclear Medicine (EANM) 
Figure 1. Correlation between results of post-induction 18F-FDG-PET 
compared to CT and the outcome at last time of follow up
Figure 2. Axial and MIP images of PET/CT and fused18F-FDG-PET/CT images of patient number 2 at initial staging showing: right mandibular mass 
lesion with SUVmax 4 associated with enlarged right cervical LNs with low grade FDG uptake
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procedure guidelines for FDG-PET/CT tumor imaging: version 
2.0 [10].
Children fasted no less than 4 hours before 18FDG injection 
dose and blood glucose level was controlled prior to the injection
The study was acquired on a Discovery LS PET/CT imaging 
system (GE Medical Systems) after intravenous administration 
of 5–7 MBq/kg of 18FDG or on a mCT Biograph imaging system 
(Siemens) following intravenous injection of 3 MBq/kg of 18FDG. 
The images were acquired from the skull to the mid-thigh ap-
proximately 60–80 min after 18FDG administration employing 3-D 
acquisition technique. Subsequent diagnostic CT images were 
used for attenuation correlation and production of fusion images. 
The images were reconstructed by ordered-subset expectation 
maximization (OSEM) iterative reconstruction algorithm with and 
without attenuation correction. 
18F-FDG-PET/CT analysis
 All 18F-FDG-PET/CT studies were reviewed by two nu-
clear medicine physicians using qualitative (visual) analysis and 
quantitative analysis using the maximum standardized uptakes 
(SUVmax) values. The SUV was calculated using the equation: 
SUV = mean activity [region of interest (ROI)] (MBq/ml) / injected 
dose (MBq) / total body weight (g). Among these SUVs from the 
targeted ROI, the SUVmax were considered as the highest SUVs of 
pixels in the ROI. Residual lesions in the 2nd 18F-FDG-PET/CT 
performed for assessment of response to therapy; are analyzed 
according to the 5 point scale as recommended by the Lugano 
criteria [11]staging, and response assessment of patients with 
Hodgkin lymphoma (HL.
The 5 point scale (5-p-s) is scored as follows: 1 = no uptake; 
2 = uptake < mediastinum; 3 = uptake > mediastinum and < liver; 
4 = uptake moderately higher than liver at any site; 5 = markedly 
increased uptake at any involved site. Scores of 4 and 5 are con-
sidered positive, while scores of 1–3 are considered negative [12].
Statistical methods
Categorical data were described as counts and percent-
ages while numerical data as SUVmax were reported as mean 
and standard deviation. Pearson’s Correlation was performed to 
examine the relationship between SUVmax and both tumor size 
and LDH level. Survival analysis was conducted by Kaplan-Meier 
method. The Overall Survival is defined as the duration from date 
of diagnosis to date of last contact or death date, while Event Free 
Survival is the duration from date of diagnosis to date of last contact 
or date of first event. Events are: developing 2ry malignancy, death, 
progression, or relapse. P values less than 0.05 in any test were 
considered to be statistically significant.
Results
Eighteen patients were included (14 males and 4 females; 
median age, 13 years), 11 had T-cell (61.1%) while 7 had B-cell 
lymphoblastic lymphoma (38.9%). Most common presentation site 
was mediastinal mass (55.5%) followed by head and neck (27.8%), 
bone marrow infiltration by < 25% blasts (11.1%) and enlarged 
inguinal LNs (5.6%).
Evaluation of 18F-FDG-PET/CT in initial staging
All lymphoma involvement lesions (n = 43) were FDG-avid 
and the intensity of nodal FDG uptake was variable. Patients’ 
Figure 3. Axial and MIP images of PET/CT and fused18F-FDG-PET/CT images of the same patient’s post induction phase showing partial response 
of the mandibular lesion SUVmax 4 , the patient was scored according to 5-ps as score 4
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characteristics with involved areas and the highest SUVmax are 
shown in Table 1.
The mean SUVmax of the involved lesions was 5.5. The higher 
SUVmax at diagnosis was most commonly observed in involved 
mediastinal lymph nodes, with a mean SUVmax of 5.7.
Two patients (11%) had BM involvement by < 25% blast 
cells with corresponding positive BM focal uptake in FDG-PET/CT 
(SUVmax = 4 and 4.5).
There was non-significant correlation between SUVmax of 
involved lesions and both tumor size (r = 0.356, p = 0.161) and 
LDH level (r = 0.347, p = 0.172). 
Evaluation of 18F-FDG-PET/CT during assessment of 
response after induction of chemotherapy
Comparison of 18F-FDG-PET/CT results and both CT and BMB 
was done post induction phase. CT detected 8 residual lesions in 
8 patients (44.5%), while FDG-PET/CT detected that only 3 of them 
(16.7%) considered Deauville-positive. 
Ten patients were in CR by CT and BMB (55.5%, n = 10) and all 
had negative 18F-FDG-PET/CT. On the other hand, 8 patients (44.5%) 
were in PR; 5 of them (27.8%) had negative 18F-FDG-PET/CT, while 
3 were positive (16.7%). No intensification of therapy was done in 
all post-induction positive patients.  
Repeated 18F-FDG-PET/CT at week 18 for post-induction pa-
tients revealed cleared all Deauville-positive residual lesions. On the 
other hand, CT at week 18 detected regression but still residual in 
4/8 (50%) post-induction CT lesions with clearance of the rest (50%).
At the time of last follow-up (mean 23.5 months), 15/18 
patients (83.3%) were alive. No patient experienced relapse or 
progression. Two patients died out of progressive infection and 
sepsis during maintenance course of chemotherapy ALL Total 
Therapy XV protocol after week 22 and 55. One patient developed 
acute myeloid leukemia (AML) after 10 weeks of maintenance 
course of chemotherapy with poor response to therapy and died 
after 4 courses of AML chemotherapy protocol; none of these 
patients had positive Deauville score post induction.
We also calculated the sensitivity, specificity, positive and nega-
tive predictive values of 18F-FDG-PET/CT in prediction of outcome 
using last clinical and radiological follow-up as control criteria. We 
found the specificity of post-induction 18F-FDG-PET/CT was 81% 
while the negative predictive value was 87% compared to 50% and 
80% for post-induction CT respectively (Fig. 1).
Survival Analysis
The 2 years OS was 80.2% (95% confidence interval 59.8% 
– 100.0%), similar to the 2 years EFS which was 80.2% (95% con-
fidence interval 59.8% – 100.0%) (Fig. 2).
Discussion
In the present study, all disease sites detected by 18F-FDG-PET 
were concordant with CT and BMB. This was similar to adult stud-
ies on lymphoblastic lymphoma where all involved lymph nodes, 
bone marrow and extra-nodal lesions were FDG-avid [13].
In the current study 18F-FDG-PET/CT did not contribute in up- or 
down-staging of any of included patients. Similar results had been 
detected in Nakatani et al study which included 3 patients with LL 
[14]. Our results also were concordant to Park et al. study on nine 
Figure 4. Axial and MIP images of PET/CT and fused 18F-FDG-PET/CT images of the mentioned patient at W18 showing complete metabolic 
remission of the involved mandibular lesion
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Table 1. Patients’ characteristics and 18F-FDG-PET/CT findings at initial staging
Pt. Gender Age Histology LDH Area with the highest SUV SUVmax Other areas involved Stage
1 Male 13 T-LL 2942 Mediastinal adenopathy 6.9 Pleura III
2 Male 16 B-LL 349 Mandibular lesion 4.5 Cervical adenopathy II
3 Female 13 B-LL 556 Skull bone 8.6 Intracranial lesion IV
4 Male 6 B-LL 1232 Both femur bones 6.2 Nasopharyngeal mass and BM IV
5 Male 11 T-LL 442 Mediastinal adenopathy 8.7 Cervical, axillary, abdominal and inguinal 
adenopathy
III
6 Male 15 T-LL 6064 Mediastinal adenopathy 9.2 Cervical, axillary, abdominal, inguinal 
adenopathy and pleura
III
7 Male 15 T-LL 1269 Mediastinal adenopathy 5.2 Cervical and inguinal adenopathy,  
renal focal lesions and pleura
III
8 Male 11 T-LL 581 Mediastinal adenopathy 2.5 Cervical and axillary adenopathy III
9 Male 15 T-LL 1162 Mediastinal adenopathy 7.3 Cervical adenopathy and pleura III
10 Female 6 T-LL 663 Mediastinal adenopathy 2.7 Pleura III
11 Male 12 B-LL 605 Cervical adenopathy 2.3 Cervical adenopathy I
12 Male 18 T-LL 500 Cervical adenopathy N/A -- I
13 Male 3 B-LL 1512 Cervical adenopathy 7.8 Abdominal adenopathy III
14 Female 13 T-LL 861 Mediastinal adenopathy 7.3 Cervical adenopathy III
15 Male 11 T-LL 467 Inguinal adenopathy 3.7 Cervical, mediastinal and abdominal 
adenopathy
III
16 Male 16 T-LL 621 Mediastinal adenopathy 2.5 -- III
17 Female 8 B-LL 539 Abdominal adenopathy 3.8 -- III
18 Male 3 B-LL 1769 Cervical adenopathy 5.3 Mediastinal adenopathy and BM IV
T-LL: T-cell Lymphoblastic Lymphomas B-LL: B-cell Lymphoblastic Lymphomas, BM: Bone Marrow, LDH: Lactate Dehydrogenase
Table 2. Response criteria using CT, 18F-FDG-PET/CT and IRC 
Pt. Response to Induction Evaluation at Week 18 Relapse/Pro-
gression
Follow up duration (months) Fate
CT and BMB FDG-PET IRC Deauville 
Score
FDG-PET CT
1 CR Negative CR 0 -- -- No 37 A
2 PR Positive PR 4 Negative Positive No 15 A
3 CR Negative CR 0 -- -- No 30 A
4 CR Negative CR 0 -- -- No 21 D
5 PR Positive PR 4 Negative Negative No 29 A
6 CR Negative CR 0 -- -- No 18 D
7 PR Negative CRu 0 -- Positive No 25 D
8 CR Negative CR 0 -- -- No 24 A
9 PR Negative CRu 0 -- Negative No 17 A
10 CR Negative CR 0 -- -- No 18 A
11 CR Negative CR 0 -- -- No 18 A
12 CR Negative CR 0 -- -- No 18 A
13 PR Negative CRu 2 -- Positive No 24 A
14 PR Negative CRu 2 -- Negative No 26 A
15 CR Negative CR 0 -- -- No 31 A
16 PR Positive PR 4 Negative Positive No 31 A
17 PR Negative CRu 0 -- Negative No 17 A
18 CR Negative CR 0 -- -- No 24 A
CT: Computed Tomography FDG-PET: Fluorodeoxyglucose Positron Emission Tomography, BMB: Bone Marrow Biopsy, IRC: International Response Criteria, CR: Complete Remission, PR: 
Partial Response, CRu: Complete Remission Uncertain, A: Alive, D: Dead
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adult Korean patients with T-LL, where no difference in staging 
occurred between FDG-PET and CT [13].
In the current study, 2 patients had bone marrow infiltration in 
both 18F-FDG-PET/CT and BMB while the other 16 patients had 
negative bone marrow in both modalities. In Park et al. study, 
eight of the studied patients were found to have bone marrow 
involvement and all had abnormal bone FDG uptake, indicating 
that 18F-FDG-PET may be useful for assessing the disease extent 
in T-LL [13].
In our study, all LL patients who did or didn’t have residual 
after induction therapy, in both 18F-FDG-PET and CT, didn’t show 
signs of progression or relapse. This was different than results by 
Jain et al. who found that all T-cell LL adult patients who had 
residual masses on PET-CT (3/22) relapsed during later phase of 
therapy (all within 6 months) and the authors concluded that such 
patients should be considered for treatment intensification [15]. 
Another study that was done by the Swedish Lymphoma 
Registry included 39 adults with T-LL, of whom none had a PET 
scan at baseline but 13 had a PET scan at various times before 
consolidation. All 13 patients were negative, but seven relapsed 
(54%). Based on this, the authors concluded that PET was not 
predictive of survival, although there was limitations in their study 
as FDG-PET/CT was not performed in a uniform manner [16]. 
A recent retrospective study by Becker et al. on adult pa-
tients with T-cell LL concluded that the five-point Deauville score 
of residual lesions after induction chemotherapy was not predic-
tive of the outcome — 7/20 of patients (35%) who had Deauville 
score ≤ 3 relapsed and in the same time 3/7 of patients (42.8%) 
had score 4–5 also relapsed [17]. 
In conclusion, in initial staging; 18F-FDG-PET/CT is a useful tool 
for disease extent evaluation of pediatric LL. Moreover, it could 
provide a diagnostic hint for BM involvement. 18F-FDG-PET/CT 
done after induction therapy has a good negative predictive value 
with higher specificity than CT alone, but is not an indication for 
treatment intensification due to false positive results. However, 
larger sample size is required for better conclusion.
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